Lindsay Androski rose to the Arbutus CEO role in 2025 after a distinguished career in biotech scale-ups and founding roles at Roivant Sciences.
Primeros años: An MIT-trained biologist, Androski built a multifaceted professional background encompassing law, finance, and scientific R&D over nearly 30 years.
Primer gran salto: Joining the founding team at Roivant Sciences, where she developed a reputation as a specialist in launching and scaling complex biotech enterprises.
Camino al CEO: Androski evolved from a legal and strategy expert into a biotech executive through leadership roles at Roivant Sciences and as CEO of Roivant Social Ventures, ultimately being tapped by Arbutus in February 2025 as part of a major board and management overhaul to sharpen the company's focus.
Visión original: To streamline Arbutus's clinical operations and maximize value from its core virology assets, particularly the LNP technology platform.
Lindsay Androski arrived at Arbutus Biopharma in February 2025, during a period of critical transition for the company. With a background spanning patent law, investment analysis (CFA), and operational leadership at high-growth entities like Roivant, she was selected to pivot the company toward its core clinical strengths. Her trajectory highlights a transition from early-stage incubator leadership—where she focused on social impact and equity—to the high-stakes, performance-driven environment of a clinical-stage virology firm.
turnaround leadbiotech expertscale-up specialist
